Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Hypercholesterolemia and SLCO1B1[original query] |
|---|
| SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. European journal of clinical pharmacology 2012 Mar 68 (3): 273-9. Santos Paulo Caleb Junior Lima, Gagliardi Ana Carolina Moron, Miname Márcio Hiroshi, Chacra Ana Paula, Santos Raul Dias, Krieger Jose Eduardo, Pereira Alexandre Cos |
| Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics 2013 Aug 14 (11): 1283-94. Lee Hon-Kit, Hu Miao, Lui Sandra Sh, Ho Chung-Shun, Wong Chun-Kwok, Tomlinson Bri |
| Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Molecular diagnosis & therapy 2013 Oct 17 (5): 299-309. Shabana Mona F, Mishriki Amal A, Issac Marianne Samir M, Bakhoum Sameh W |
| No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Molecular biology reports 2014 Jul 41 (7): 4631-8. Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis A D, Elisaf M, Kolovou G, Manolopoulos V |
| POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics 2014 Dec 15 (16): 1963-72. Drogari Euridiki, Ragia Georgia, Mollaki Vasiliki, Elens Laure, Van Schaik Ron H N, Manolopoulos Vangelis |
| SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. International journal of molecular sciences 2015 16 (9): 20609-19. Prado Yalena, Saavedra Nicolás, Zambrano Tomás, Lagos Jenny, Rosales Alexy, Salazar Luis |
| The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmacogenomics and personalized medicine 2016 9 59-63. Sychev Dmitrij Alekseevitch, Shuev Grigorij Nikolaevich, Chertovskih Jana Valer'evna, Maksimova Nadezhda Romanovna, Grachev Andrej Vladimirovich, Syrkova Ol'ga Aleksandrov |
| Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug metabolism and personalized therapy 2018 Feb . Alghalyini Baraa, El Shamieh Said, Salami Ali, Visvikis Siest Sophie, Fakhoury Hana M, Fakhoury Raj |
| Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical pharmacology and therapeutics 2019 Jun 105 (6): 1501-1512. Wagner Jonathan B, Abdel-Rahman Susan, Gaedigk Roger, Gaedigk Andrea, Raghuveer Geetha, Staggs Vincent S, Kauffman Ralph, Van Haandel Leon, Leeder J Stev |
| A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. European journal of clinical pharmacology 2019 Jun . Ogungbenro Kayode, Wagner Jonathan B, Abdel-Rahman Susan, Leeder J Steven, Galetin Aleksand |
| Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients. Drug metabolism and pharmacokinetics 2019 Aug . Lee Nora, Maeda Kazuya, Fukizawa Shinya, Ieiri Ichiro, Tomaru Atsuko, Akao Hironobu, Takeda Kenji, Iwadare Mizuho, Niwa Osamu, Masauji Tougen, Yamane Naoe, Kajinami Kouji, Kusuhara Hiroyuki, Sugiyama Yuic |
| Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin. European journal of clinical pharmacology 2020 May . Zhang Dan, Ding Yangming, Wang Xiaoxue, Xin Wenyu, Du Wenwen, Chen Wenqian, Zhang Xianglin, Li Pengm |
| Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clinical and translational science 2020 Jan . Wagner Jonathan B, Abdel-Rahman Susan, Gaedigk Andrea, Gaedigk Roger, Raghuveer Geetha, Staggs Vincent S, Van Haandel Leon, Leeder J Stev |
| SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability. Journal of personalized medicine 2021 Mar 11 (3): . Zubiaur Pablo, Benedicto Maria Dolores, Villapalos-García Gonzalo, Navares-Gómez Marcos, Mejía-Abril Gina, Román Manuel, Martín-Vílchez Samuel, Ochoa Dolores, Abad-Santos Francis |
| Atorvastatin-associated rhabdomyolysis in a patient with a novel variant of the SLCO1B1 gene: A case report. Journal of clinical lipidology 2021 12 16 (1): 23-27. Kiage James, Venkatanarayan Ajay, Roth Mendel, Elam Marsha |
| Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism. Archives of pharmacal research 2023 12 . Chang-Keun Cho, Ju Yeon Mo, Eunvin Ko, Pureum Kang, Choon-Gon Jang, Seok-Yong Lee, Yun Jeong Lee, Jung-Woo Bae, Chang-Ik Ch |
| SLCO1B1 Genetic Variation Influence on Atorvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Genes 2024 1 15 (1): . Jonathan B Wagner, Susan Abdel-Rahman, Geetha Raghuveer, Andrea Gaedigk, Erin C Boone, Roger Gaedigk, Vincent S Staggs, Gregory A Reed, Na Zhang, J Steven Leed |
- Page last reviewed:Feb 1, 2024
- Content source: